GILD - Gilead Sciences Stock Price, News & Analysis

$72.82 0.31 (0.43 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$72.51
Today's Range$72.35 - $73.09
52-Week Range$63.76 - $86.27
Volume4.37 million shs
Average Volume9.29 million shs
Market Capitalization$95.12 billion
P/E Ratio7.6
Dividend Yield2.87%

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs


Debt-to-Equity Ratio1.10%
Current Ratio3.68%
Quick Ratio3.56%


Trailing P/E Ratio7.6
Forward P/E Ratio8.54
P/E Growth-1.22

Sales & Book Value

Annual Sales$30.39 billion
Price / Sales3.13
Cash Flow$12.60 per share
Price / Cash5.78
Book Value$19.33 per share
Price / Book3.77


Annual Dividend$2.08
Dividend Yield2.9%


Trailing EPS$8.78
Net Income$13.50 billion
Net Margins41.65%
Return on Equity45.88%
Return on Assets17.41%


Outstanding Shares1,306,270,000

Frequently Asked Questions for Gilead Sciences (NASDAQ:GILD)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Thursday, October 26th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.52 per share on Thursday, December 28th. This represents a $2.08 annualized dividend and a dividend yield of 2.87%. The ex-dividend date is Thursday, December 14th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) posted its earnings results on Thursday, October, 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.13 by $0.14. The biopharmaceutical company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a net margin of 41.65% and a return on equity of 45.88%. The company's revenue was down 13.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.75 EPS. View Gilead Sciences' Earnings History.

When will Gilead Sciences make its next earnings announcement?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Gilead Sciences.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?

27 Wall Street analysts have issued 1 year price objectives for Gilead Sciences' stock. Their predictions range from $68.00 to $96.00. On average, they anticipate Gilead Sciences' share price to reach $85.17 in the next twelve months. View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

  • 1. According to Zacks Investment Research, "Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni. However, the HCV franchise continued to witness slowdown as a result of competitive and pricing pressure. Higher discounts and payer mix continue to hurt sales. The company expects that the persistent decline in HCV patient starts will impact sales along with increased competition which will impact both patient share and pricing. While the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens, Gilead will lose exclusivity for Viread in 2017 in some countries which should impact sales. TOn a positive note, Gilead recently acquired Kite Pharma to foray into the CAR T therapy space which represents immense potential at this juncture . Shares of the company have outperformed the industry so far in 2017." (10/18/2017)
  • 2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
  • 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
  • 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)

Are investors shorting Gilead Sciences?

Gilead Sciences saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 19,599,824 shares, a drop of 18.9% from the October 13th total of 24,156,580 shares. Based on an average trading volume of 10,442,870 shares, the short-interest ratio is currently 1.9 days. Currently, 1.5% of the company's stock are short sold.

Who are some of Gilead Sciences' key competitors?

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:

  • John C. Martin Ph.D., Executive Chairman of the Board
  • John F. Milligan Ph.D., Chief Executive Officer, Director
  • Robin L. Washington, Chief Financial Officer, Executive Vice President
  • Kevin B. Young, Chief Operating Officer
  • Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
  • Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs
  • James R. Meyers, Executive Vice President - Worldwide Commercial Operations
  • John F. Cogan Jr. Ph.D., Lead Independent Director
  • Kelly A. Kramer, Independent Director
  • Kevin E. Lofton, Independent Director

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (2.30%), Parnassus Investments CA (1.43%), Capital International Investors (0.86%), Boston Partners (0.80%), Legal & General Group Plc (0.54%) and American International Group Inc. (0.49%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan, Bank of New York Mellon Corp, Parnassus Investments CA, American Century Companies Inc., Principal Financial Group Inc., Woodford Investment Management Ltd, Bessemer Group Inc. and Schroder Investment Management Group. Company insiders that have sold Gilead Sciences company stock in the last year include Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Sanders Capital LLC, Skandinaviska Enskilda Banken AB publ, Ameriprise Financial Inc., Amundi Pioneer Asset Management Inc., Assenagon Asset Management S.A., Pictet Asset Management Ltd. and Mondrian Investment Partners LTD. View Insider Buying and Selling for Gilead Sciences.

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of Gilead Sciences stock can currently be purchased for approximately $72.46.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $95.12 billion and generates $30.39 billion in revenue each year. The biopharmaceutical company earns $13.50 billion in net income (profit) each year or $8.78 on an earnings per share basis. Gilead Sciences employs 9,000 workers across the globe.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DR, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

MarketBeat Community Rating for Gilead Sciences (GILD)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  1,619 (Vote Outperform)
Underperform Votes:  587 (Vote Underperform)
Total Votes:  2,206
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Gilead Sciences (NASDAQ:GILD)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.652.652.702.63
Ratings Breakdown: 1 Sell Ratings
12 Hold Ratings
19 Buy Ratings
2 Strong Buy Ratings
1 Sell Ratings
12 Hold Ratings
19 Buy Ratings
2 Strong Buy Ratings
0 Sell Ratings
12 Hold Ratings
19 Buy Ratings
2 Strong Buy Ratings
0 Sell Ratings
12 Hold Ratings
17 Buy Ratings
1 Strong Buy Ratings
Consensus Price Target: $85.32$87.04$82.48$83.86
Price Target Upside: 15.65% upside8.66% upside14.38% upside26.95% upside

Consensus Price Target History for Gilead Sciences (NASDAQ:GILD)

Price Target History for Gilead Sciences (NASDAQ:GILD)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)

DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017ArgusDowngradeBuy -> Hold$73.25 -> $73.77N/AView Rating Details
11/8/2017MizuhoBoost Price TargetBuy$77.00 -> $83.00N/AView Rating Details
10/27/2017Maxim GroupReiterated RatingHoldN/AView Rating Details
10/27/2017BMO Capital MarketsLower Price TargetOutperform$89.00 -> $83.00N/AView Rating Details
10/25/2017J P Morgan Chase & CoSet Price TargetBuy$85.00N/AView Rating Details
10/19/2017Leerink SwannBoost Price TargetMarket Perform$84.00 -> $85.00N/AView Rating Details
10/19/2017William BlairReiterated RatingBuyN/AView Rating Details
10/19/2017Berenberg BankSet Price TargetBuy$96.00N/AView Rating Details
10/11/2017Barclays PLCReiterated RatingOverweight -> Overweight$90.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$77.00 -> $83.00N/AView Rating Details
10/5/2017CIBCInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
10/5/2017Oppenheimer Holdings, Inc.Initiated CoverageMarket PerformN/AView Rating Details
10/5/2017Jefferies Group LLCInitiated CoverageHold -> PositiveN/AView Rating Details
10/4/2017Bank of America CorporationLower Price TargetNeutral$87.00 -> $86.00LowView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$94.00LowView Rating Details
9/6/2017Wells Fargo & CompanyBoost Price TargetMarket Perform$73.00 -> $81.00LowView Rating Details
8/31/2017Cowen IncReiterated RatingOutperform$90.00MediumView Rating Details
8/31/2017Deutsche Bank AGReiterated RatingBuy$81.00MediumView Rating Details
8/28/2017Needham & Company LLCReiterated RatingHoldLowView Rating Details
8/29/2017Robert W. BairdReiterated RatingOutperform$87.00LowView Rating Details
8/29/2017Credit Suisse GroupReiterated RatingOutperform$79.00 -> $85.00MediumView Rating Details
7/26/2017Redburn PartnersInitiated CoverageBuyMediumView Rating Details
5/3/2017GabelliReiterated RatingBuy$85.00MediumView Rating Details
5/3/2017Stifel NicolausReiterated RatingBuy$87.00MediumView Rating Details
4/21/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
3/13/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$70.00 -> $68.00LowView Rating Details
2/8/2017Citigroup Inc.DowngradeBuy -> Neutral$87.00 -> $76.00N/AView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00N/AView Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyN/AView Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00N/AView Rating Details
(Data available from 11/24/2015 forward)


Earnings History and Estimates Chart for Gilead Sciences (NASDAQ:GILD)

Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)

Earnings History by Quarter for Gilead Sciences (NASDAQ GILD)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018$1.71N/AView Earnings Details
10/26/2017Q3 2017$2.13$2.27$6.40 billion$6.51 billionViewN/AView Earnings Details
7/26/2017Q2 2017$2.11$2.56$6.35 billion$7.14 billionViewN/AView Earnings Details
5/2/2017Q1 2017$2.18$2.20$6.66 billion$6.51 billionViewListenView Earnings Details
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.78$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.27$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.61$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.75$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
2017 EPS Consensus Estimate: $8.10
2018 EPS Consensus Estimate: $6.58
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$2.09$2.42$2.23
Q2 20173$2.01$2.29$2.15
Q3 20174$1.86$2.10$1.96
Q4 20174$1.66$1.85$1.76
Q1 20182$1.58$1.78$1.68
Q2 20182$1.54$1.76$1.65
Q3 20182$1.49$1.74$1.62
Q4 20182$1.52$1.74$1.63
(Data provided by Zacks Investment Research)


Current Dividend Information for Gilead Sciences (NASDAQ:GILD)

Next Dividend:12/28/2017
Annual Dividend:$2.08
Dividend Yield:2.86%
Payout Ratio:23.69% (Trailing 12 Months of Earnings)
24.38% (Based on This Year's Estimates)
30.95% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Dividend History by Quarter for Gilead Sciences (NASDAQ GILD)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Gilead Sciences (NASDAQ GILD)

Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 76.30%
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Insider Trades by Quarter for Gilead Sciences (NASDAQ GILD)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2017John F MilliganInsiderSell220,000$72.88$16,033,600.00View SEC Filing  
11/1/2017Gregg H AltonEVPSell15,000$74.82$1,122,300.00View SEC Filing  
11/1/2017John C MartinInsiderSell73,333$75.13$5,509,508.29View SEC Filing  
10/2/2017Gregg H AltonEVPSell25,000$82.65$2,066,250.00View SEC Filing  
10/2/2017John C MartinInsiderSell73,333$82.56$6,054,372.48View SEC Filing  
9/7/2017Robin L WashingtonCFOSell51,820$85.00$4,404,700.00View SEC Filing  
9/1/2017Gregg H AltonEVPSell25,000$83.05$2,076,250.00View SEC Filing  
9/1/2017John C MartinInsiderSell73,333$83.11$6,094,705.63View SEC Filing  
8/31/2017James R MeyersEVPSell60,000$83.19$4,991,400.00View SEC Filing  
8/30/2017Gregg H AltonEVPSell50,000$79.00$3,950,000.00View SEC Filing  
8/1/2017Gregg H AltonEVPSell15,000$75.88$1,138,200.00View SEC Filing  
8/1/2017John C MartinInsiderSell73,333$75.86$5,563,041.38View SEC Filing  
7/21/2017Gregg H AltonEVPSell40,000$74.00$2,960,000.00View SEC Filing  
7/3/2017Gregg H AltonEVPSell5,000$71.06$355,300.00View SEC Filing  
7/3/2017John C MartinInsiderSell73,333$71.00$5,206,643.00View SEC Filing  
5/9/2017John Francis CoganDirectorSell9,943$67.25$668,666.75View SEC Filing  
4/3/2017John C MartinInsiderSell73,333$67.18$4,926,510.94View SEC Filing  
3/30/2017Gregg H AltonEVPSell5,000$67.48$337,400.00View SEC Filing  
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.83View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.00View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Gilead Sciences (NASDAQ GILD)

J&J & Glaxo's Jucala Approval Puts Spotlight on HIV SpaceJ&J & Glaxo's Jucala Approval Puts Spotlight on HIV Space - November 24 at 4:42 PM
Gilead: Attractive After Big Retreat? - Seeking AlphaGilead: Attractive After Big Retreat? - Seeking Alpha - November 24 at 10:23 AM
Can Gilead Sciences Inc’s (GILD) ROE Continue To Surpass The Industry Average?Can Gilead Sciences Inc’s (GILD) ROE Continue To Surpass The Industry Average? - November 23 at 4:36 PM
J&J & Glaxo Get FDA Approval for First Two-Drug HIV RegimenJ&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen - November 22 at 7:53 PM
Gilead: The Leader of the Pack…or Just Another Follower?Gilead: The Leader of the Pack…or Just Another Follower? - November 22 at 7:53 PM
How Merck’s Zepatier and Isentress Are PositionedHow Merck’s Zepatier and Isentress Are Positioned - November 21 at 7:03 PM
The 1 Thing Missing From Gilead Sciences' 2018 Priority ListThe 1 Thing Missing From Gilead Sciences' 2018 Priority List - November 21 at 7:03 PM
The 1 Thing Missing From Gilead Sciences 2018 Priority ListThe 1 Thing Missing From Gilead Sciences' 2018 Priority List - November 21 at 1:13 PM
Gilead Sciences Enters Oversold TerritoryGilead Sciences Enters Oversold Territory - November 20 at 7:40 PM
Gilead Sciences (GILD) a Sell on Falling Sales GrowthGilead Sciences (GILD) a Sell on Falling Sales Growth - November 20 at 1:28 PM
Your Daily Pharma Scoop: Gilead CAR-T Potential, Egalet Surges, Aerie Launches Mid-Stage StudyYour Daily Pharma Scoop: Gilead CAR-T Potential, Egalet Surges, Aerie Launches Mid-Stage Study - November 17 at 11:57 AM
Watch Out Gilead, Junos Strategy Might Just Pay Off - Seeking AlphaWatch Out Gilead, Juno's Strategy Might Just Pay Off - Seeking Alpha - November 16 at 7:44 PM
Trade of the Day: Gilead Sciences, Inc. (GILD) - Investorplace.comTrade of the Day: Gilead Sciences, Inc. (GILD) - - November 16 at 7:44 PM
Biotech Industry: Small Innovators Outflank Big Caps As Blockbuster Drug Patent Cliff LoomsBiotech Industry: Small Innovators Outflank Big Caps As Blockbuster Drug Patent Cliff Looms - November 16 at 7:44 PM
Gilead Sciences Inc (GILD) President and CEO John F Milligan Sold $16 million of SharesGilead Sciences Inc (GILD) President and CEO John F Milligan Sold $16 million of Shares - November 16 at 2:41 PM
John F. Milligan Sells 220,000 Shares of Gilead Sciences, Inc. (GILD) StockJohn F. Milligan Sells 220,000 Shares of Gilead Sciences, Inc. (GILD) Stock - November 15 at 7:31 PM
Trade of the Day: Gilead Sciences, Inc. (GILD)Trade of the Day: Gilead Sciences, Inc. (GILD) - November 15 at 9:43 AM
GILD Makes Notable Cross Below Critical Moving AverageGILD Makes Notable Cross Below Critical Moving Average - November 14 at 7:39 PM
As Gileads Outlook Dims, Argus DowngradesAs Gilead's Outlook Dims, Argus Downgrades - November 13 at 5:44 PM
Gilead: Falling Sales+Higher Spending=Lower ProfitsGilead: Falling Sales+Higher Spending=Lower Profits - November 13 at 5:44 PM
Analysis of Industry Group Rank Keep Gilead Sciences (GILD) a SellAnalysis of Industry Group Rank Keep Gilead Sciences (GILD) a Sell - November 13 at 12:30 PM
Top Analyst Upgrades and Downgrades: Best Buy, Equifax, Gilead, MongoDB, NVIDIA, Rio Tinto, Teva, UPS and MoreTop Analyst Upgrades and Downgrades: Best Buy, Equifax, Gilead, MongoDB, NVIDIA, Rio Tinto, Teva, UPS and More - November 13 at 9:39 AM
Gilead Sciences, Inc. (GILD) Stock Rating Lowered by ArgusGilead Sciences, Inc. (GILD) Stock Rating Lowered by Argus - November 13 at 8:48 AM
Gilead Sciences, Inc. (GILD) Given Consensus Recommendation of "Buy" by BrokeragesGilead Sciences, Inc. (GILD) Given Consensus Recommendation of "Buy" by Brokerages - November 12 at 11:40 AM
3 Top Biotech Stocks for 20183 Top Biotech Stocks for 2018 - November 12 at 9:55 AM
Gilead Sciences, Inc. (GILD) Short Interest Down 18.9% in OctoberGilead Sciences, Inc. (GILD) Short Interest Down 18.9% in October - November 12 at 1:32 AM
Youll Be Stunned by Gilead Sciences CEOs Prediction for 2018You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018 - November 9 at 8:56 AM
$5.70 Billion in Sales Expected for Gilead Sciences, Inc. (GILD) This Quarter$5.70 Billion in Sales Expected for Gilead Sciences, Inc. (GILD) This Quarter - November 8 at 2:30 AM
Research Analysts Offer Predictions for Gilead Sciences, Inc.s FY2020 Earnings (GILD)Research Analysts Offer Predictions for Gilead Sciences, Inc.'s FY2020 Earnings (GILD) - November 7 at 4:44 PM
Glaxo vs Gilead: Put Em Up?Glaxo vs Gilead: Put 'Em Up? - November 7 at 1:08 AM
Bluebird: Can It Keep Singing?Bluebird: Can It Keep Singing? - November 7 at 1:08 AM
Gilead Sciences, Inc. (GILD) Expected to Announce Earnings of $1.70 Per ShareGilead Sciences, Inc. (GILD) Expected to Announce Earnings of $1.70 Per Share - November 6 at 11:26 PM
Rating on Gilead Sciences (GILD) Stock Drops to SellRating on Gilead Sciences (GILD) Stock Drops to Sell - November 6 at 1:43 PM
Gilead Sciences, Inc. (GILD) Insider Sells $5,509,508.29 in StockGilead Sciences, Inc. (GILD) Insider Sells $5,509,508.29 in Stock - November 3 at 8:36 PM
Gregg H. Alton Sells 15,000 Shares of Gilead Sciences, Inc. (GILD) StockGregg H. Alton Sells 15,000 Shares of Gilead Sciences, Inc. (GILD) Stock - November 3 at 8:36 PM
Gilead’s Hepatitis C Drugs: Performances in 3Q17Gilead’s Hepatitis C Drugs: Performances in 3Q17 - November 3 at 9:33 AM
How Gilead’s Drugs Performed in 3Q17How Gilead’s Drugs Performed in 3Q17 - November 3 at 9:33 AM
Financial Analysis: Gilead Sciences (GILD) and The CompetitionFinancial Analysis: Gilead Sciences (GILD) and The Competition - November 3 at 3:18 AM
What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October? - November 2 at 9:17 PM
Why Juno Therapeutics Shares Are Going Up 21.2% Today Why Juno Therapeutics Shares Are Going Up 21.2% Today - November 2 at 3:25 PM
Whats Behind Gilead Sciences Inc.s $7.8 Billion Slide in October?What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October? - November 2 at 3:25 PM
Gilead Is Persona Non Grata - Seeking AlphaGilead Is Persona Non Grata - Seeking Alpha - November 1 at 8:35 PM
[$$] Risk, Reward and the Pricing of New Drugs[$$] Risk, Reward and the Pricing of New Drugs - November 1 at 8:35 PM
Spring Bank Caps Off Breakout Year With Potential HBV Cure, But Dont Forget STINGSpring Bank Caps Off Breakout Year With Potential HBV Cure, But Don't Forget STING - November 1 at 1:55 PM
How Gilead Sciences Performed in 3Q17How Gilead Sciences Performed in 3Q17 - October 31 at 8:13 PM
Gilead’s TAF-Containing HIV Products Saw Solid Growth in 3Q17Gilead’s TAF-Containing HIV Products Saw Solid Growth in 3Q17 - October 31 at 8:12 PM
Gilead’s HIV Drugs Atripla, Truvada, and Stribild in 3Q17Gilead’s HIV Drugs Atripla, Truvada, and Stribild in 3Q17 - October 31 at 8:12 PM
Rating for Gilead Sciences (GILD) Drops From a Hold to Sell - Investorplace.comRating for Gilead Sciences (GILD) Drops From a Hold to Sell - - October 31 at 5:59 AM
Rating for Gilead Sciences (GILD) Drops From a Hold to SellRating for Gilead Sciences (GILD) Drops From a Hold to Sell - October 30 at 12:59 PM
Gilead Sciences, Inc. (GILD) Stock Isnt Worth It Here - Investorplace.comGilead Sciences, Inc. (GILD) Stock Isn't Worth It Here - - October 29 at 11:09 PM

Social Media



Gilead Sciences (NASDAQ GILD) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.